<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="375">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    https://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 16, 2016</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01051037</url>
  </required_header>
  <id_info>
    <org_study_id>09-08-026</org_study_id>
    <nct_id>NCT01051037</nct_id>
  </id_info>
  <brief_title>Stereotactic Body Radiotherapy and Radiofrequency Ablation for Lung Tumors Near Central Airways</brief_title>
  <official_title>Phase II Study Evaluating Safety and Efficacy of Stereotactic Body Radiotherapy and Radiofrequency Ablation for Medically Inoperable and Recurrent Lung Tumors Near Central Airways</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Jonsson Comprehensive Cancer Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Jonsson Comprehensive Cancer Center</source>
  <oversight_info>
    <authority>United States: Food and Drug Administration</authority>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to demonstrate that combined stereotactic body radiotherapy and
      radiofrequency ablation is safe for patients with lung tumors near central airways.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>February 2010</start_date>
  <primary_completion_date type="Anticipated">August 2017</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <study_design>Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment</study_design>
  <primary_outcome>
    <measure>Achieve at most of 20% subacute or chronic grade 3 or higher lng, cardiac, or upper GI toxicity rate in patients treated with SBRT/RFA.</measure>
    <time_frame>3 years</time_frame>
    <safety_issue>Yes</safety_issue>
  </primary_outcome>
  <secondary_outcome>
    <measure>Achieve no more than 15% decline from the pre-treatment pulmonary function parameter (FEV1, DLCO) post-SBRT/RFA.</measure>
    <time_frame>3 years</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Achieve at least a 80% one-year local control (LC) rate by RECIST criterion or PET response (if applicable).</measure>
    <time_frame>3 years</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Progression-free survival</measure>
    <time_frame>3 years</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall survival</measure>
    <time_frame>3 years</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Concentration of serum TGF-B as early biomarker for treatment-inducted normal tissue injury</measure>
    <time_frame>3 years</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Concentration of serum VEGF as an early biomarker for response</measure>
    <time_frame>3 years</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">35</enrollment>
  <condition>Lung Cancer</condition>
  <arm_group>
    <arm_group_label>Arm 1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Subjects will undergo PET/CT simulation, 3 Fraction SBRT, RFA, and then undergo follow up.</description>
  </arm_group>
  <intervention>
    <intervention_type>Radiation</intervention_type>
    <intervention_name>Stereotactic Body Radiation</intervention_name>
    <description>3 fraction of stereotactic body radiation therapy within 10 days.</description>
    <arm_group_label>Arm 1</arm_group_label>
    <other_name>SBR</other_name>
  </intervention>
  <intervention>
    <intervention_type>Radiation</intervention_type>
    <intervention_name>Radiofrequency Ablation</intervention_name>
    <description>Subject will undergo radiofrequency ablation within 10 days of the last fraction of SBRT.</description>
    <arm_group_label>Arm 1</arm_group_label>
    <other_name>RFA</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Histologically confirmed primary lung cancer, lung metastasis from another primary,
             or recurrent tumors in the setting of prior RFA or cryotherapy

          -  Tumors &lt; 2 cm from trachea or zone of proximal bronchial tree (central tumors)

          -  Each tumor &lt; 5 cm in size prior to treatment

          -  Medically inoperable patients as determined at the multidisciplinary thoracic tumor
             board, or medically operable patients who refuse surgery

          -  Criterion for medical inoperability include:

               -  Overall clinical assessment at the UCLA thoracic tumor board

               -  Reduced Pulmonary Function (FEV1, DLCO, etc) based on one major or two minor
                  criterion as described below:

          -  Modified ACOSOG Criteria for medical inoperability:

               -  Major Criteria: FEV1% &lt; 50% or &lt; 1L and DLCO &lt; 50%

               -  Minor Criteria: Age &gt; 75, FEV1 51-60% predicted, or FEV1 1-1.2L, DLCO 51%-60%
                  predicted, pulmonary hypertension, poor left ventricular function (EF &lt; 40% or
                  less), resting or exercise arterial pO2 &lt; 55 mmHg, and pCO2 &gt; 45 mmHg

          -  Age &gt; 18 years old

          -  KPS &gt; 70

          -  If a woman is of childbearing potential, a negative urine or serum pregnancy test
             must be documented.

          -  Ability to understand and the willingness to sign a written informed consent

        Exclusion Criteria:

          -  Prior thoracic radiation near the targets of interest

          -  More than 2 central tumor targets per patient

          -  Active infections requiring systemic antibiotics
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Percy Lee, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of California, Los Angeles</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Percy Lee, MD</last_name>
    <phone>310-206-6542</phone>
  </overall_contact>
  <location>
    <facility>
      <name>UCLA Jonsson Comprehensive Cancer Center</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90095</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Percy Lee, MD</last_name>
      <phone>310-206-6542</phone>
    </contact>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>March 2016</verification_date>
  <lastchanged_date>March 4, 2016</lastchanged_date>
  <firstreceived_date>January 15, 2010</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>lung tumors</keyword>
  <keyword>central airways</keyword>
  <is_fda_regulated>Yes</is_fda_regulated>
  <is_section_801>Yes</is_section_801>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Lung Neoplasms</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
